Human Trials Initiated for Pioneering AI-Generated Drug

A entirely artificial intelligence-generated drug has entered Phase II human clinical trials for the first time. In 2020, INS018_055 was discovered and is being evaluated as a treatment for idiopathic pulmonary fibrosis, a chronic lung disease.

INS018_055, created by the biotech corporation Insilico Medicine, is the first drug whose purpose and design were generated by artificial intelligence. In addition, it centers on a disease whose exact cause is unknown, whose prevalence has increased in recent decades, and which, if left untreated, can result in death within two to five years. 100,000 individuals in the United States suffer from idiopathic pulmonary fibrosis.

Insilico is a Hong Kong-based venture that has received funding in excess of $400 million. Its founder, Alex Zhavoronkov, told CNBC that current treatments for IPF focus on slowing its progression and can cause uncomfortable side effects, so they decided to focus on this drug despite having two others designed by AI: one against covid-19. 19, which is in phase I clinical trials, and another against cancer, specifically a “USP1 inhibitor for the treatment of solid tumors” that just received FDA approval to begin clinical trials in the United States.

Insilico created the algorithms and technology it uses to discover and design novel molecules internally, then decided to conduct clinical trials to demonstrate the technology’s efficacy.

In China, randomized patients are participating in a 12-week, double-blind, placebo-controlled trial of INS018_055. Insilico intends to expand the trial to the United States in order to enroll a total of sixty patients. If the phase II trial is successful, which will be determined the following year, a larger phase III study with hundreds of participants will be conducted the following year.

Zhavoronkov stated, “We believe this drug will reach the market for patients who can benefit from it within the next few years.”

Subscribe to Our Latest Newsletter

To Read Our Exclusive Content, Sign up Now.
$5/Monthly, $50/Yearly

RECENT POSTS

Irfan Pathan Predicts Top Batter and Top Bowler of ODI World Cup 2023

The cricketing world is humming with anticipation as the...

9 New Features of iPhone 15 That Are First-Ever in Smartphones

Some of the most significant changes to the iPhone...

Nobel Prize 2023 in Physics Awarded for Breakthrough in Atomic Imaging

The 2023 Nobel Prize in Physics was awarded to...

Google Pixel Buds Pro Review: Features, Pricing, and Comparison [Detail Guide]

Are you interested in the latest, most advanced wireless...

Top 200 Alternatives to TioAnime for Watching Free Animes in 2023

Welcome to the world of Tioanime, where you can...

ASTROLOGY

LIFESTYLE

BUSINESS

TECHNOLOGY

HEALTH

FEATURED STORIES